✦ LIBER ✦

PCN34 PHARMAECONOMIC EVALUATION OF THE USE OF ERLOTINIB IN NON-SMALL CELLS LUNG CANCER (NSCLC) WITH FAILURE TO PREVIOUS CHEMOTHERAPY

✍ Scribed by C Tenorio; J Vargas; MI Pacheco; L González-Michaca

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN89 Economic Evaluation of Erlotinib a

✍ Lechuga, D.; Alva, M.; Sanchez-Kobashi, R.; Gay, J.G. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

PCN76 Economic Evaluation of the Use of

✍ Lechuga, D.; Alva, M.; Gay, J.G.; Sánchez-Kobashi, R. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

PCN12 COST EFFECTIVENESS OF ERLOTINIB IN

✍ E Orlewska; A Szczesna; M Gyldmark; M Szkultecka-Debek 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 66 KB

PCN77 COST-EFFECTIVENESS ANALYSIS OF ERL

✍ TE Ciuleanu; M Dediu; LN Minea; S Baculea; M Szkultecka-Debek 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB

PCN58 A COST UTILITY ANALYSIS OF ERLOTIN

✍ PA Bradbury; R Jang; P Isogai; R Ng; N Mittmann; W Evans; FA Shepherd; NB Leighl 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB

PCN77 PHARMACOECONOMIC ANALYSIS OF ERLOT

✍ O Batigun; E Yildirim 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 75 KB